GSK: FDA approves FLUARIX QUADRIVALENT

GSK said that the FDA approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine. Fluarix Quadrivalent is the first intramuscular vaccine to cover against four influenza strains. Dr. Leonard Friedland , VP and Head, GSK North America Vaccines Clinical Development and Medical Affairs, said, “Trivalent influenza vaccines have helped protect millions of people against flu, but in six of the last 11 flu seasons, the predominant circulating influenza B strain was not the strain that public health authorities selected. Fluarix Quadrivalent will help protect individuals against both B strains and from a public-health standpoint, can help decrease the burden of disease.”

http://www.prnewswire.com/news-releases/fda-approves-glaxosmithklines-four-strain-seasonal-influenza-vaccine-for-use-in-the-us-183790471.html